nM). Only at higher concentrations
has nimodipine been reported to block the release of some neurotransmitters and hormones from neuronal tissue. Nimodipine has no consistent effect on brain oxygen consumption or cortical ATP or phosphocreatine levels, although the ischemia-induced fall of brain ATP levels in gerbils or the lowering of intracellular brain pH in rabbits with focal cerebral ischemia were antagonized by the drug.
In rats and baboons with middle cerebral artery occlusion, nimodipine was found to reduce neurological deficits without an increase in intracranial pressure or brain edema. Electrophysiological studies with nimodipine suggested a direct neuronal action. In rabbit dorsal root ganglion cells, concentrations as low as 20 nM were reported to block inward Ca2 currents. Recent studies have suggested that nimodipine may also improve memory in brain-damaged or old rats, restore sensorimotor function and abnormal walking patterns of old rats, and accelerate acquisition of associative learning in aging rabbits. Blockade of age-related changes in Ca2' fluxes in rat hippocampal neurones by nimodipine in vitro pointed to neuronal plasma membrane as the site of nimodipine action. The therapeutic usefulness of nimodipine appears not to be limited to cerebral ischemia, but may include dementia, age-related degenerative diseases, epilepsy, and ethanol intoxication. The neuronal effect of CAs appears to be mediated through slowly inactivating Ca2 channels (L-type) whose blockade leads to a reduction of Ca2 entry into neurons. The FASEBJournal SCRIABINE ET AL.
[3H]Nimodipine was shown to bind to cardiac, smooth, and skeletal muscle and brain membrane preparations. The binding was saturable, reversible, and stereospecific.
In guinea pig brain membranes, is not yet clear.
EFFECTS ON CEREBRAL METABOLISM
At concentrations of up to 1 tM, nimodipine had no effect on oxygen consumption by isolated brain slices (4). At 1 mg/kg i.p., nimodipine had no effect on cortical ATP (Fig. 1) . However, the total number of errors was significantly smaller in the nimodipinetreated rats than in the vehicle-treated control animals. Also, the swimming time of nimodipine-treated rats decreased more than that of the vehicle-treated animals. Subsequently, the effects of long-term treatment with nimodipine on the behavior of old rats were studied. Nimodipine was mixed with the rat food at 860 ppm (ca. 35 mg.kg1
.day1).
In the first experiment, old rats were fed regular food or food containing nimodipine for 6 to 9 months starting at the age of 24 months.
After 4 wk, the exploratory behavior of rats in an unfamiliar observation cage was studied. Old rats showed a lower level of exploration in the novel environment than younger animals, but nimodipine-treated rats crossed significantly more squares than did the old rats that were fed normally, and the occurrence of rearing was higher. Also, the duration of inactivity was significantly longer in the drug-treated group (Fig. 2) . After a single oral treatment with 15 mg/kg nimodipine, the exploratory behavior was not enhanced in either old or young animals. Thus, this effect is not a stimulatory (amphetamine-like) effect on behavior. During the course of the feeding experiment, the same rats were tested several times for sensorimotor function using balance rods and vertical plane. Old rats showed significant impairment of sensorimotor functions; the nimodipine-treated rats performed significantly better in all tests. The difference between treated and untreated rats was most evident during the first 12 wk of the experiment (57). At the age of about 27 months, another deficit became apparent in most rats when they showed abnormal walking patterns.
To study this in more detail, a footprint test originally developed for the examination of neurological deficits of young rats after injuries of the sciatic nerve was used with old rats. The hind paws of rats were dipped into photographic developer so that the animals left clearly visible footprints on the photographic paper. Footprints of old rats were fuzzy because of rotation of the hind paw after placement on the paper and dragging hind legs (Fig. 3) . The incidence of abnormal foot- 
months nimodipine
. At the end of the experiment, however, when the rats were more than 30 months old, the incidence of abnormal footprints increased in the drug-treated rats also. To study the pathology of the abnormal footprints, nerve conduction velocities in sciatic nerves of the old rats were examined.
Nerve conduction velocity of untreated 27-month-old rats (50 m/s) was significantly lower than in 3-month-old rats (80 m/s). The mean conduction velocity of the nimodipine-treated old rats (66 m/s) was significantly higher than that of the control animals of the same age and barely lower than that of the young ones. Histological examinations of cross sections of the sciatic nerves revealed that fiber density in the nimodipine-treated group was significantly higher than in control animals of the same age (R. Gerritsen van der Hoop, C. E. E. M. van Landfield (60) reported that in isolated CAl hippocampal neurons from aged (but not young) rats, the Ca2-dependent afterhyperpolarization and the Ca2 spikes are prolonged, and that this component of Ca2 influx is sensitive to nimodipine. The behavioral effects of nimodipine in brain-damaged and old animals described above strongly suggest the therapeutic usefulness of nimodipine in brain dysfunction associated with trauma or aging.
ANTICONVULSANT ACTIVITY
In initial pharmacological studies, orally administered nimodipine was reported to antagonize pentylenetetrazole but not electroshock-induced convulsions in mice (6).
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In Ca2 currents are resistant to CAs (e.g., are not affected by nimodipine even at 1 ILM), indicating potential for a high degree of tissue specificity. There are substantial differences in the relative effectiveness of various GAs in the CNS. These differences are determined to a great extent by the physical properties of individual drugs (e.g., lipophiicity) and, consequently, by their ability to cross the blood-brain barrier. Such differences are known to exist even among DHPs. The volume of distribution of nimodipine in the brain of rats was shown to be threefold higher than that of nifedipine (65 
